Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LHF-535 in Healthy Participants
NCT03993704Phase 1Completed
- Sponsor
- Kineta Inc.
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ARN-75039 in Lassa fever (4 arms), sponsored by Kineta Inc. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events at 42 days. Started Sep 2019; status: completed.
02
Drugs
ARN-75039
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT03993704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993704.